Utepreva

Utepreva is a clinical-stage biotechnology company focused on the development of novel therapeutics for women's health, specifically targeting uterine fibroids and endometriosis. The company's lead candidate is telapristone acetate, a selective progesterone receptor modulator (SPRM) that aims to provide a non-surgical alternative for managing chronic gynecological conditions. By modulating progesterone activity, the treatment is designed to reduce heavy menstrual bleeding and alleviate pelvic pain while maintaining a manageable safety profile. Utepreva was established by a team of industry veterans with extensive experience in hormonal therapies and reproductive medicine. The company is currently advancing its clinical programs to address significant unmet needs in the treatment of benign uterine conditions.